Executive Vice President, International Operations
Raymond Francot joined the company in January 2018. He previously served as Myriad’s Chief Commercial Officer in Europe. Prior to joining Myriad, Mr. Francot was vice president and regional general manager for Vertex Pharmaceuticals GmbH. Prior to Vertex, he was general manager at Gilead Sciences Germany GmbH, where he developed the company’s HIV franchise in Germany, Austria and Switzerland. Mr. Francot’s first role in the life sciences industry was with Baxter Healthcare where he held various international commercial positions within the renal division. Mr. Francot received his undergraduate and master’s degrees in law studies from the University of Maastricht and a master’s in business administration from Erasmus University of Rotterdam.
Business Unit Manager & Iberia Medical Director
Noni Angulo joined Myriad Genetics in October 2012. Ms. Angulo has more than 15 years of experience in the Spanish public and private healthcare system as a practitioner in different autonomous communities. Since 2015, she established marketing, medical and sales operations at Myriad España. Since 2018, she conducted all Iberia operations, starting the Myriad business in Portugal and the Spanish Quality program for EndoPredict. Ms. Angulo obtained a Medical degree in 1993 from the State University of Malaga, and holds since 2000 the Radiation Oncologist specialization after training as a resident in Hospital Doce de Octubre in Madrid, where she worked as an Associate Professor for Doctoral and Degree courses. In 2009, she obtained a Master Degree in Senology. She also followed the SEOM training for Hereditary Cancer.
Country Manager, Italy
Franco Boretti joined the company in January 2012. Mr. Boretti has more than 25 year of experience in the healthcare industry. He established marketing operations and served as General Manager in Italy at BRAHMS, a division of Thermo Fisher Scientific and prior to that at Quidel, where he was appointed General Manager for the South of Europe. He also worked for Chiron as Sales and Marketing Manager in Italy and for the pharmaceutical company Recordati as global Licensing Manager. Mr. Boretti holds a Master’s degree in Pharmaceutical Chemistry and Technology from the State University of Milan.
Lucas F.J. Dürselen
Business Director, D-A-CH
Lucas Dürselen joined Myriad in April 2015 and has long-time experience in the healthcare business in German speaking countries. He is responsible for Myriad’s commercial operations in Germany, Austria and Switzerland. Before joining Myriad, Mr. Dürselen was member of the board of the Amedes Group, one of the market leaders in laboratory diagnostics, pathology and human genetics. In this role, he was responsible for the company’s Commercial Operations in Germany and Belgium.
Prior to joining Amedes, Mr. Dürselen was more than 10 years General Manager at DxD Consulting, a consultancy company active in the field of optimizing medical processes and implementation of quality assurance methods within hospitals and large medical institutions. Mr. Dürselen’s first roles in industry were with Hamilton Bonaduz AG where he held various international scientific and commercial positions in the sensor division.
Lucas Dürselen studied Chemistry at the University of Tübingen, received the doctoral degree (Dr. sc. nat.) from the Swiss Federal Institute of Technology (ETH) at Zurich and has a MBA from the University of St. Gallen (Switzerland).
Vice President International Market Access & Advocacy
Benjamin Gannon joined Myriad Genetics in March 2019 and is responsible for international market access, policy and advocacy. He has over 20 years of European and international experience from the life sciences industry. Before joining Myriad, Mr Gannon was responsible for international government affairs, policy and patient engagement with Vertex Pharmaceuticals. In this role, he established and was responsible for government affairs and patient engagement for Vertex’ operations internationally – this included support to market access strategy and regulatory policy relevant to the portfolio and rare diseases sector. Mr Gannon is a Board member of EUCOPE, the European Confederation of Pharmaceutical Industries.
Before joining Vertex, Mr Gannon was Vice President for Group Public Affairs for SCA and has held senior government affairs and policy roles with Gilead, Johnson & Johnson and GlaxoSmithKline. Mr Gannon is a dual German / UK national and holds Bachelor and Masters degrees in Biology from Southampton University (UK) and Imperial College (UK) respectively.
Country Manager, Canada
Mark Hammar joined Myriad Genetics July 1, 2019. Mark brings more than 30 years’ experience in sales, marketing, reimbursement and country leadership with Pfizer, Agouron, Astellas, BD, Lupin and other multinational healthcare companies in Canada to this position.
Gary A. King
Country Manager, Japan
Gary A. King joined the company in July 2010 and has been employed in the life sciences industry for more than 35 years. Prior to Myriad, he was the Chief Executive Officer of AverDx Incorporated, an international biotechnology company. Before AverDx, he was Vice President, International Operations at Biosite Incorporated where he spent six years building and leading all of the Company’s commercial activities outside the United States. Prior to joining Biosite, Mr. King was Division Director in Japan for Guidant Corporation and led Guidant’s transition from distributor to direct operations in the Japanese market. Mr. King received his Bachelor of Arts degree in Zoology from Pomona College and a Masters of Business Administration degree from Stanford University.
Senior Director, France, Belux, Maghreb
Patrick Korman joined Myriad Genetics in November 2011. Initially Mr. Korman led the international market access and public affairs activities as well as supporting global business development, and was responsible for licensing key technologies for our companion diagnostics program.
He is now focusing on France as business and team are growing significantly since the first Myriad product is reimbursed in the country. Mr. Korman has been employed in the life sciences industry for 30 years. He served as CEO in a French biotech company, Fluigent, a spin-off of Curie Institute, and prior to that, he was CEO at Alexion Pharmaceutical France from the startup of the company and a Senior Member of Alexion Europe Leadership Team, spending 3 years establishing the business from MAA to pricing and first years of sales. Prior to Alexion, he built an extensive experience of the Pharma industry as VP in different international consulting firms. Mr. Korman has an MA Political Sciences and MBA from HEC.
Director, International Medical Affairs
Ralf Kronenwett joined Myriad Genetics with the acquisition of Sividon Diagnostics in June 2016 and holds the position of Director International Medical Affairs. He received his medical degree from the University of Heidelberg. After serving as a resident physician at the University Hospital Heidelberg, Ralf Kronenwett was a research group leader at the Clinical Cooperation Unit Molecular Hematology/Oncology of the German Cancer Research Centre in Heidelberg. In 1999, he moved to the University Hospital Dusseldorf, qualified as an Assistant Professor of Molecular Medicine and focused on molecular therapeutics and diagnostics in hematology/oncology as well as biology and therapeutic use of hematopoietic stem cells. From 2006 to 2010, he held positions as senior scientist at Bayer HealthCare and Siemens Healthcare Diagnostics and was working on prognostic and predictive biomarkers in breast cancer. In 2010, Ralf Kronenwett co-founded Sividon Diagnostics GmbH and held the positions of the Chief Medical Officer and Chief Scientific Officer (CMO/CSO). He was responsible for Medical Affairs, for R&D activities and for the development of the breast cancer prognosis test EndoPredict. Ralf Kronenwett was involved in several international research projects and is a coauthor of more than 90 research journal publications.
Compliance Officer, International Markets
Abdul joined Myriad in October 2019 as a member of the Myriad Corporate Compliance & Privacy organisation. Abdul is responsible for providing support and guidance to the Myriad International business unit in the areas of data privacy and security, anti-bribery and corruption and compliance with legal and industry standards governing interactions with health care professionals. Prior to joining Myriad, Abdul worked for more than 25 years in the life sciences industry with the likes of Johnson & Johnson, Rhone-Poulenc and Astellas. Abdul holds a Ph.D. in synthetic organic chemistry and an MBA.
Executive Director, International Sales
Lawrence Murphy joined Myriad Genetics in April 2012. Mr. Murphy has worked in the Commercial Life Sciences / Biotechnology sector for the last 18 years. Previous to his time with Myriad Genetics, Mr. Murphy worked in sales for several years at Life Technologies / Invitrogen in Australia before moving to the UK where he joined an Australian Biotechnology instrument Manufacturer €” Corbett Research for nearly 9 years establishing their UK operations and building a team of Salespeople and Engineers. In another tenure within the same company he moved on to establishing the distributor networks for Corbett Research in Asia-Pacific where he focused mostly on China, South Korea, Japan & India and worked closely with them to develop sales across the region. Lawrence also spent several years based back in London with Illumina a Next Generation Sequencing & Microarray leader establishing their Distributor Network across Europe, Russia, The Middle East and South Africa. Mr. Murphy has also spent more than 5 years working in Laboratory Research as well working on a variety of projects from Asian Schistosomiasis Vaccine development to Environmental Toxicology to Plant AgriGenomics. Mr. Murphy gained a Bachelor of Applied Science majoring in Molecular Biology / Genetics at the Queensland University of Technology in Brisbane Australia.
Director Customer and Kits Operations
Frank Nowas has worked in various roles within the In-Vitro-Diagnostics and Life Science industry for 21 years. After many years in technical field service and product support functions with Beckman Coulter in Europe, he became European Project Manager for laboratory automation and led later on the Clinical Diagnostics Service Germany West. He then spent nearly five years with the German subsidiary of Waters Inc. as National Service Manager. There he managed Field Service, Customer Support and Customer training. Excellent customer service for clinical customers, pharmaceutical and chemistry industry, universities and public institutions have been the main focus of his work there. Most recently, Mr. Nowas served as Director Services International in the area of gastroenterology. His responsibilities contained optimization of customer service for direct customers and distributors throughout the world, continuous improvement to the repair center as well as creating technical support capabilities outside Europe.
Mr. Nowas received his diploma in Biomedical Engineering from the University of Applied Science in Aachen.
Country Manager, UK and Ireland
David’s scientific career began in drug discovery following a PhD and Post-doctoral research in synthetic organic chemistry. After some years as a medicinal chemist, David moved into a more commercial role before joining Fisher Scientific UK Ltd as a sales representative. Following an MBA at Imperial College, London focused on healthcare, David Joined MeadWestvaco a world leading packaging manufacturer in business development progressing to European Sales Director for the Adherence Packaging and Pump Dispenser business. A second spell at Thermo Fisher Scientific saw David managing the UK, Ireland and Netherlands Clinical Diagnostics business, bringing together the innovative biomarker business with the well-established Drugs of Abuse and quality controls portfolio. David brings a good deal of experience in UK market access, having worked closely with NICE, the NIHR Diagnostic Evidence Cooperatives and NHS England. He has expertise in Health Economics, Decision Impact modelling and guideline processes.